Pharm - Coagulation Disorders Flashcards
COX inhibitors (antiplatelet drugs)
Aspirin (Ibuprofen)
ADP P2Y12 inhibitors (Antiplatelet drugs)
Clopidogrel, Ticlopidine, (Prasugrel)
Phosphodiesterase Inhibitors (Antiplatelet drugs)
Dipyridamole (Boner Pills)
GpIIb/IIIa inhibitors (antiplatelet drugs)
Abciximab, Eptifibatide (Tirofiban)
PAR-1 inhibitors (Antiplatelet drugs)
Vorapaxar
Aspirin MOA
irreversible COX-1 inhibitor, reduces TxA2 production, reduces platelet aggregation
P2Y12 receptor antagonists MOA
Clopidogrel, Ticlopidine, Prasugrel –> block effect of ADP at receptor, inhibit platelet function/activation/aggregation
GpIIb/IIIa antagonists MOA
Abciximab, Eptifibatide, Tirofiban –> block binding of fibrinogen to activated platelet receptor
PDE inhibitor MOA
Dipyridamole –> inhibits the catalysis of cAMP and cGMP –> elevated cAMP levels inhibit platelet function
PAR-1 antagonist MOA
Vorapaxar –> block thrombin-induced platelet aggregation
Major adv effects of platelet inhibitors
bleeding
Contraindications to use of platelet inhibitors
pts w/ conditions pre-disposing them to bleeding –> PMH of active pathological bleeding, trauma, surgery,
Aspirin and Ibuprofen - both act on COX - which one is irreversible? (and other one is reversible)
Aspirin = irreversible (ibuprofen = reversible)
What effect does aspirin have on the PT or PTT?
none
Why does aspirin have specificity for the platelet? (B/c endothelial cells have COX also)
platelets are anucleat –> have no ability to recover from COX inhibition, b/c cannot synthesize more. Endothelial cells can regenerate COX
What do endothelial cells COX produce, why is it impt?
PGI2, it inhibits platelet action
What does the dose/response profile for aspirin look like compared to the dose/risk profile? (Idk how to ask this question)
there is no additional clinical effect w/ increased dose, only increase risk
Adverse effects of aspirin
GI related, they are dose dependent –> severely toxic in high doses (suicide), hepatic and renal toxicity
contraindications for aspirin use
previous hx of aspirin-induced bronchospasm
what happens when ADP binds the P2Y12 receptor on platelet surface
inhibition of adenylyl cyclase –> lower levels of cAMP, platelets have less inhibition
P2Y12 inhibitors - reversible or irreversible
Clopidogrel, Ticlopidine, Prasugrel –> irreversible
–> persistence of effect ~10 days
black box warning for Clopidogrel
poor Cyp2C9 metabolizers –> at risk for reduced response, genetic tests available
black box warning for Ticlopidine
second line tx due to life threatening hematologic toxicities –> agranulocytosis, neutropenia, thrombocytopenia, TTP, anemia
route of excretion for the P2Y12 inhibitors
Clopidogrel, Ticlopidine, Prasugrel –> hepatic/renal elimination
PDE inhibitor MOA
Dipyridamole –> induce elevations in cAMP –> block release of AA from membrane phospholipids, reduce TxA2 –> less inhibition of platelets
also, stimulates release PGI2 (prostacyclin) which induces adenylate cyclase, thus raising cAMP levels , inhibit platelet aggregation even more
Sweatman quote about Dipyridamole
“It is uninteresting w/ regards to adverse effects”
GpIIb/IIIa inhibitors route of admin
Abciximab, Eptifibatide, Tirofiban –> IV
Abciximab
Fab fragment of chimeric monoclonal Ab –> NONCOMPETITIVE (causes steric hindrance, conformational change) of GpIIb/IIIa site
Abciximab reversible or irreversible
irreversible - protracted duration up to 2 weeks
Reactions seen to these GpIIb/IIIa antagonists
Abciximab, Eptifibatide, Tirofiban –> anaphylactic reactions
adv effect seen with Abciximab
thrombocytopenia –> numan anti-chimeric Ab formation to abciximab
PAR-1 antagonist route of admin
Vorapaxar –> oral
Vorapaxar half life / reversibility
technically reversible –> but t1/2 = 8 days –> effectively irreversible
Vorapaxar persistence
up to 4 weeks –> Holding a dose will do NOTHING to correct bleeding or reduce risk
PAR-1 antagonist metabolism/elimination
Vorapaxar –> hepatic metabolism (3A4) - fecal elimination
Herbal Product Interactions w/ antiplatelet drugs
Ginkgo Biloba - antiplatelet properties
garlic - antiplatelet properties
ginger - inhibits TxA synthetase, a platelet aggregation inducer
indirect thrombin inhibitors (anticoagulant drugs)
Heparin
Heparin antidote
protamine sulfate
direct thrombin inhibitors (anticoagulant drugs)
Dabigatran (Bivalirudin, Lepirudin)
Factor Xa inhibitors (anticoagulant drugs)
Enoxaparin, Apixaban, Rivaroxaban (Fondaparinux)
inhibitor of clotting factor synthesis (anticoagulant drug)
Warfarin
Warfarin antidotes
prothrombin complex, Phytonadione vit K1
Heparin route of admin
IV
Heparin structure
glycosaminoglycan - chains of alternating D-glucosamine and uronic acid
what does Heparin bind
binds ATIII (Antithrombin) (and also thrombin, form ternary complex)
Heparin MOA
causes conformational change in Antithrombin (ATIII) accelerates ability of ATIII to inactivate thrombin, factor Xa, and factor IXa
which clotting factor is least sensitive to action of Heparin
thrombin
what is the structure of what is going on when heparin is indirectly inhibiting thrombin?
ternary complex –> heparin/ATIII complex binds to thrombin
How is the MOA of heparin on Factor Xa different?
inactivation of factor Xa does not require heparin/ATIII complex (I think he means it does not require “ternary complex” formation)
low molecular weight heparin
enoxaparin
enoxaparin MOA
catalyzes inhibition of factor Xa by ATIII
enoxaparin cannot do…
cannot accelerate inactivation of thrombin by ATIII (not long enough to form ternary complex)
major adv effects of heparin
bleeding, THROMBOCYTOPENIA - immune mediated (HIT - heparin induced thrombocytopenia)
what are you worried about with the LMWH
NOT thrombocytopenia –> much lower risk of thrombocytpenia w/ LMWH
other possible adv effect w/ both unfractionated hep and LMWH
anaphylactic reactions –> derived from animal products, may be antigenic
Monitoring Heparin drug dosing
aPTT
Monitoring LMWH
(enoxaparin) - lower impact on aPTT test, instead use Factor Xa assay
can you give Hep for outpatient?
No
antidote for Heparin
Protamine
what is the antidote for Hep derived from?
Protamine is derived from fish sperm
who do you need to be careful of with protamine
ppl with a fish hypersensitivity –> b/c it is derived from fish sperm
which enantiomer of Warfarin is more potent
S
route of admin for Warfarin
oral –> can give outpatient
warfarin MOA
inhibits hepatic synthesis of vit K dependent coagulation factors II, VII, IX, and X, and proteins C and S
What specifically does warfarin act on
the C1 subunit of the vit K epoxide reductase (VKORC1) enzyme – is a genetic variable
result of warfarin therapy
depletion of reduced form of vit K –> limits gamma-carboxylation of vit K dependent coag proteins
what does warfarin onset depend on?
persistence of individual cofactors already formed
Which factors deplete first/quickest
Protein C and S, which are anticoagulant - this necessitates bridging therapy
bridgin therapy with Warfarin
must co-admin Heparin to prevent initial hypercoagulable state caused by warfarin depleting protein C and S
Monitoring clinical activity of warfarin
PT assay
Pharmacokinetic issues with warfarin
CYP2C9 inhibitors or inducers affect levels of active s-warfarin –> Cimetidine (OTC) inhibitor CYP activity, bleed into urine
Pharmacogenetics of warfarin
CYP2C9 and VKROC1 –> variability in pt response –> African Americans may have 2C9 allele not currently tested for
Heparin vs Warfarin - which has a longer duration of actioin?
Warfarin - chronic duration, on the order of days
site and speed of action for hep and warfarin
hep - blood, rapid
warfarin - liver, slow
Hep v Warfarin - teratogenecity
warfarin - cannot use during pregnancy
heparin = “happy” during pregnancy
Apixaban, Rivaroxaban MOA
bind to and directly inhibit factor Xa –> thrombin inhibition
do Apixaban and Rivaroxaban require ATIII?
no
clinical utility of direct factor Xa inhibitors
Apixaban, Rivaroxaban –> tx and prophylaxis of DVT and PE, stroke prophylaxis
Apixaban, Rivaroxaban route of admin
oral
toxicity of Apixaban, Rivaroxaban
Bleeding –> no reversal agent available
Fondaparinux MOA
bind to ATIII which inhibits factor Xa (indirectly), –> thrombin inhibition
Fondaparinux route of admin
IV or SC
clinical utility of indirect factor Xa inhibitors
Fondaparinux - tx and prophylaxis of DVT and PE; stroke prophylaxis
Fondaparinux toxicity
bleeding –> no reversal agent available
Dabigatran, Bivalirudin, Lepirudin MOA
bind to and directly inhibit both free and clot-bound thrombin
Route of Admin for Dabigatran
oral (other direct thrombin inhibitors are IV)
Dabigatran toxicity
bleeding; no reversal agent
Apixaban, Rivaroxaban pharmacokinetics
metabolized through Cyp, potential drug-drug interactions
Dabigatran ADME shit
can interact w/ P-gp inhibitors or inducers
Warfarin antagonists
Phytonadione; Vit K1
Prothrombin complex concentrate (PCC)
Phytonadione vit K1 MOA
identical to natural K vitamins
Phytonadione clinical utility
prophylaxis or tx of hemorrhage, hemorrhagic diseases of newborn, hypoprothrombinemia, nutritional supplementation and vit K deficiency
Prothrombin complex concentrate componenets
factors II, VII, IX, and X - antithrombotic proteins C and S
plasminogen activators (thrombolytic drugs)
Alteplase, t-PA (Reteplase, Tenecteplase, streptokinase)
inhibitors of fibrinolysis (thrombolytic drugs)
aminocaproic acid
Alteplase (and derivatives) MOA
specific in activating fibrin-bound plasminogen
streptokinase MOA
has no specificity for fibrin-bound plasminogen –> has the ability to activate both free and fibrin-bound forms
activation of circulating plasminogen results..
generation of activated plasmin that overwhelms alpha2-antiplasmin -
what can unopposed plasmin in circulation do
trigger a systemic lytic state
drugs that are products of recombinant genetic technology
drugs ending in “-plase”
use of thrombolytics
early MI, early ischemic stroke, direct thrombolysis of severe PE
thrombolytics adverse events
bleeding - internal, intacranial, retroperitoneal, GI, GU, respiratory
Aminocaproic Acid
antifibrinolytic drug - use for hemorrhage and hyperfibrinolysis
aminocaproic acid MOA
blocks conversion of plasminogen to plasmin
aminocaproic acid metabolism and elimination
hepatic metabolism, hepatic/renal elimination
Aminocaproic acid adv effects
short term adversity to CV system, especially when IV
aminocaproic acid contraindicated
DIC or active intracascular clotting w/out concurrent use of heparin
aminocaproic acid - monitor cardiac patients
hypotension and bradycardia may occur if you slam the IV